PositiveID, Leicos to Use PCR in DTRA Contract
News Apr 25, 2014
The multiple-award indefinite delivery/indefinite quantity ("ID/IQ") contract has a five-year base period of performance, a five year option, and a total value of approximately $4 billion for all awardees, if all options are exercised. The contract was awarded under the Combating Weapons of Mass Destruction Research and Technology Development ID/IQ contract.
In October 2012, PositiveID entered into a Teaming Agreement with Leidos, which paired Leidos' system engineering and integration capabilities withPositiveID's bio-threat detection technologies. PositiveID will offer both its Firefly Dx handheld diagnostic system ("Firefly") as well as its M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector as part of the Teaming Agreement.
PositiveID's M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) continuously and autonomously analyzes air samples for the detection of biological airborne threats in the form of bacteria, viruses, and toxins. The technology was developed under contract with the "DHS" Science & Technology directorate, and is designed to detect the release of pathogens into the air as part of a defense against potential terrorist attacks.
PositiveID's Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results using real-time TaqMan® PCR (polymerase chain reaction) chemistry. Firefly is being developed to meet the growing need in healthcare and molecular diagnostics markets for more rapid and accurate point-of-need diagnostics that will enable hospitals, physicians and other providers to save lives. Firefly can derive results from a sample in less than 20 minutes, at the point of need, compared to two to four hours for a lab device, which would enable accurate diagnostics leading to more rapid and effective treatment than what is currently available with existing systems.
William J. Caragol, Chairman and CEO of PositiveID, stated, "We are very pleased that our teaming partner, Leidos, has been awarded this significant ID/IQ contract, and we look forward to demonstrating the ability of our Firefly and M-BAND technologies to combat weapons of mass destruction."
DTRA is the U.S. Department of Defense's Combat Support Agency for countering weapons of mass destruction. The agency's experts address the entire spectrum of chemical, biological, radiological, nuclear and high yield explosive threats. Under the contract, Leidos will perform research and technology development to provide scientific and technological solutions to meet the DoD's non-proliferation, counterproliferation, and consequence management objectives. Leidos is one of seven contractors eligible to compete for task orders under the contract.
PositiveID and Leidos are parties to a contractor team arrangement pursuant to the Federal Acquisition Regulations and are not joint venturers, partners in a legal partnership or otherwise affiliated.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019